Bluebird Bio (BLUE) |
|
28.68 0.74 (2.65%)
|
03-07 04:19 |
|
Open: |
28.1 |
Pre. Close: |
27.94 |
|
High:
|
28.76 |
Low:
|
26.18 |
|
Volume:
|
1,708,384 |
Market Cap:
|
1,926M |
|
|
|
|
bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
28.801 - 28.962 |
28.962 - 29.11 |
|
Low:
|
25.781 - 25.979 |
25.979 - 26.16 |
|
Close:
|
28.371 - 28.68 |
28.68 - 28.963 |
|
Technical analysis |
as of: 2021-03-05 5:05:39 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 46.13 One year: 57.14 |
| Support: |
Support1: 24.24 Support2: 20.17 |
| Resistance: |
Resistance1: 39.49 Resistance2: 48.92 |
| Pivot: |
29.30  |
| Moving Average: |
MA(5): 29.37 MA(20): 33.70
MA(100): 45.08 MA(250): 52.79 |
| MACD: |
MACD(12,26): -4.27 Signal(9): -4.44 |
| Stochastic oscillator: |
%K(14,3): 19.47 %D(3): 21.88 |
| RSI: |
RSI(14): 33.59 |
| 52-week: |
High: 72.51 Low: 24.24 Change(%): -54.6 |
| Average Vol(K): |
3-Month: 206442 10-Days: 358946 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.BLUE has closed above bottom band by 46.7%. Bollinger Bands are 66.6% wider than normal. The large width of the bands suggest high volatility as compared to BLUE's normal range. The bands have been in this wide range for 13 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 05 Mar 2021
bluebird bio Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (BLUE); Lead Plaintiff Deadline is April 13, 2021 - Yahoo Finance
Fri, 26 Feb 2021
bluebird bio to Present at Cowen Health Care Conference - Yahoo Finance
Fri, 26 Feb 2021
Bluebird bio pares losses after suggesting lentiviral vector didn’t cause blood cancer - Seeking Alpha
Wed, 24 Feb 2021
Is There Any Hope for bluebird bio Stock? - Motley Fool
Tue, 23 Feb 2021
bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress - Yahoo Finance
Wed, 17 Feb 2021
BLUE Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies bluebird bio, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
66 |
| Shares Float (M) |
66 |
|
% Held by Insiders
|
0.50 |
|
% Held by Institutions
|
97.55 |
|
Shares Short (K)
|
6,140 |
|
Shares Short P. Month (K)
|
6,950 |
Stock Financials |
|
EPS
|
-10.810 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
22.960 |
|
Profit Margin
|
-256.84 |
|
Operating Margin
|
-261.48 |
|
Return on Assets (ttm)
|
-21.3 |
|
Return on Equity (ttm)
|
-42.9 |
|
Qtrly Rev. Growth
|
116.3 |
|
Gross Profit (p.s.)
|
-8.166 |
|
Sales Per Share
|
3.776 |
|
EBITDA (p.s.)
|
-9.636 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-474 |
|
Levered Free Cash Flow (M)
|
-290 |
Stock Valuations |
|
PE Ratio
|
-2.65 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.25 |
|
Price to Sales
|
7.60 |
|
Price to Cash Flow
|
-4.01 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
